Direction is in our DNA
10 July 2015, Lindy Bosch, Business Developer
“Direction is so much more important than speed. Many are going nowhere fast”.
In my opinion, this quote recently displayed on social media describes exactly what we at SMS-oncology stand for. In the past few months we have been quite busy to implement our 4D concept to emphasize that we deliver a service that is beyond what is offered by the majority of other CROs. We provide an extra ‘D’ to our clients in the complex drug development pathway – namely that of ‘Direction’ – to navigate the path forward to discover and leverage the full potential of our client’s oncology drugs.
In order for SMS-oncology to be able to provide direction requires our team to comprise of oncology experts who can think ahead of the game and in line with our client’s needs. Therefore we are particularly excited to introduce our new colleagues Nadina Grosios, Jasmijn Hubers and Analyn Animo, strengthening our company.
We are pleased for Nadina Grosios (PhD, MPH) to represent SMS-oncology in her position of Director Consultancy. Nadina has over 15 years experience in drug development within industry and academia and her career has progressed from basic cancer research across the whole spectrum of translational research to pre- and clinical studies and post-registration activities. Following the completion of her PhD in cancer pharmacology and postdoctoral fellowship in molecular aspects of cancer angiogenesis, she worked on various drug development projects (lead optimization to Phase III), moving to technical to strategic and leadership roles in her different positions at international pharmaceutical companies, before starting at SMS-oncology in March 2015.
Jasmijn Hubers (MD, PhD) reinforces SMS-oncology in her combined position of Medical Monitor / Pharmacovigilance Manager. Jasmijn obtained her medical degree and conducted research on the referral process for genetic counseling in breast cancer patients during her study Medicine. She devoted five years on the evaluation of sputum biomarkers for lung cancer diagnosis for which she received her PhD. Jumpstarting her career in industry at a small biotech company as research physician, she gained experience in phase II drug trials, before joining SMS-oncology in February 2015.
Last month, Analyn Animo joined SMS-oncology to supervise the data management unit dedicated to early phase trials in her position as Head Data Management. With her 15 years of clinical data management experience in her (manager) positions at international CROs she was responsible for setting up and implementing several SOPs and standards, and had both a training and advisory role to project teams regarding the operational data management and clinical programming aspects during projects.
At SMS-oncology we believe that great work comes from passion and dedication. With our growing team having direction embedded in our DNA, we hope to contribute to your successful drug development path in the near future as well.